What question did this study set out to answer?

The aim is to evaluate the shift from antibiotic-based treatments to early biologic therapy in hidradenitis suppurativa.

Early biological therapy in hidradenitis suppurativa: A commentary

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the shift from antibiotic-based treatments to early biologic therapy in hidradenitis suppurativa.
Review of current understanding of hidradenitis suppurativa pathogenesis.
Assessment of prescription patterns and expert opinions through a survey of European specialists.
Analysis of therapeutic efficacy of anti-TNF-α agents and IL-17 inhibitors.
Antibiotics often fail to control disease activity in mild hidradenitis suppurativa.
79% of specialists support short-term biologic therapy over antibiotics.
Clarity on biologic use in early-stage disease is sought by 95% of clinicians.

No takes yet. Share an insight, caveat, or question.

Commentary examines the effectiveness of early biologic therapy in hidradenitis suppurativa, suggesting implications for treatment strategy.

Scala et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Commentary examines the effectiveness of early biologic therapy in hidradenitis suppurativa, suggesting implications for treatment strategy.